Davita Inc vs Toast Inc. Class A Common Stock — how do they compare? Davita Inc trades at $180.7 (market cap $11.62B), while Toast Inc. Class A Common Stock trades at $29.53 (market cap $17.85B). The key difference: Toast Inc. Class A Common Stock is the larger of the two by market cap, and Davita Inc is trading nearer its 52-week high, Toast Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Toast Inc. Class A Common Stock for 0 Days on average.
| DVA | TOST | |
|---|---|---|
Market Cap | $11.62B | $17.85B |
Volume | 400,903 | 6,311,718 |
Sector | Health | Technology |
52-Week High | $240.96 | $39.02 |
52-Week Low | $103.87 | $22.33 |
Typical Hold Time | 114 Days | 0 Days |
Enterprise Value | $24.33B | $16.10B |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $180.70, down 0.59% today, with strong fundamental performance including three consecutive quarterly earnings beats and a 15.43 P/E ratio. The stock shows bullish technical signals with moving averages supporting upward momentum, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent partnership expansion with Humana for value-based kidney care represents significant business development.
DVA presents compelling value with analyst consensus target of $235.67 offering 30% upside potential, supported by Warren Buffett's substantial ownership. Key risks include rising debt-to-asset ratio reaching 65.55% and regulatory pressures in healthcare. The combination of earnings momentum, institutional support, and reasonable valuation creates favorable investment conditions despite margin compression concerns.
Toast (TOST) trades at $30.89, down 1.37% on the day, with neutral technical indicators showing support at $30 and resistance at $32. The company demonstrates strong fundamental performance with 23% revenue growth in Q2 2026 to $1.91B and expanding profit margins, though valuation metrics remain elevated with a P/E of 39.1. Recent expansion into convenience stores with Toast Fuel and AI-driven product enhancements signal continued growth initiatives.
The outlook remains positive with 61.8% analyst buy ratings and a $38.22 consensus price target representing 24% upside potential. Key risks include execution challenges in new market segments and competitive pressures in the restaurant technology space, while strong earnings beats and institutional support provide confidence in the growth trajectory.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Toast Inc. provides a cloud-based technology platform for the restaurant industry, combining point-of-sale hardware and software with payment processing, online ordering, payroll, and supplier management tools. The platform serves restaurants ranging from single locations to multi-unit groups across US.
Read more on TOST →